Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie-Hélène Perez has a total of 608 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Analgesia, sedation, and mobilization practices in pediatric patients supported with extracorporeal membrane oxygenation across Europe: an ESPNIC survey

    by Francesca Cavagnero, Aparna Hoskote, Jon Lillie, Luc Morin, Felix Neunhoeffer, Paloma Dorao, Martin Kneyber, Tiphaine Corbisier, János Schnur, Maria-Helena Perez, et al.

    Appropriate analgosedation and mobilization are essential elements of care in critically ill children. On extracorporeal membrane oxygenation (ECMO), analgosedation and mobilization are tailored to individual pharmacokinetics and mobilization risks. We aimed to investigate analgosedation and mobilization practices in pediatric ECMO across Europe. We performed a multicenter cross-sectional survey-based study. We surveyed one experienced physician per pediatric ECMO center in Europe (March–July 2025). Additionally, we investigated differences in practices based on ECMO volume (≤ 10 vs > 10 cases/year) and ICU type (exclusively pediatric ICU vs other ICUs). Among 123 ECMO centers, 96 (77%) responded, across 19 countries. Fifty-two percent of centers managed > 10 ECMO/year; 68% had exclusively pediatric ICUs. Nineteen percent of centers had a dedicated ECMO-analgosedation protocol. Most centers applied the same analgesic (81%) and sedative (80%) strategies used for non-ECMO patients, though higher doses were often reached on ECMO (62%). Morphine and fentanyl were the preferred first-line analgesics, with fentanyl more used in exclusively pediatric ICUs (p = 0.013); midazolam was the preferred first-line sedative (61%) followed by dexmedetomidine (24%); dexmedetomidine, propofol, and ketamine were the most used second- and third-line agents. Analgosedation, iatrogenic withdrawal, and delirium monitoring tools were widely used, yet 16% and 26% of centers did not use any iatrogenic withdrawal syndrome or delirium tools, respectively. Eighty-one percent of centers implemented mobilization; higher ECMO-volume centers implemented mobilization (p = 0.022), awake-ECMO strategies (p = 0.041), and proning (p = 0.009) more frequently compared to lower ECMO-volume centers. Conclusions: Management of analgosedation in pediatric ECMO patients mirrors that used for non-ECMO patients, though higher doses are reached on ECMO. Only 19% of the centers have a dedicated ECMO-analgosedation protocol. Midazolam is still widely used over alpha-agonists. Mobilization practices are particularly implemented in higher ECMO-volume centers. Further research and education are needed to define best practices and improve outcomes for this population. What is Known: • Appropriate analgosedation and mobilization are essential elements of care in critically ill children. On ECMO, analgosedation and mobilization are challenging and should be tailored to individual pharmacokinetics and mobilization risks. • Limited data, evidence, and dedicated guidelines exist on this topic. What is New: • Management of analgosedation in pediatric ECMO patients in Europe largely mirrors that used for non-ECMO patients, though higher maximum doses were reached on ECMO. Only 19% of centers have a dedicated analgosedation protocol for ECMO-patients. Morphine and fentanyl are the most used analgesics. Midazolam is still widely used as first-line sedative, despite recent pediatric guidelines advocating for alpha-agonists. Mobilization practices are particularly implemented in centers with higher ECMO-volume, reflecting a broader cultural shift toward minimizing sedation and promoting rehabilitation. • Further research and standardized education are needed to define best practices and ultimately improve outcomes for this high-risk patient population.

  • Open Access

    Corrigenda: Pain, Agitation, Delirium, and Iatrogenic Withdrawal Syndrome Management in Children Who Are Critically Ill: Protocol for a European Clinical Practice Guideline Using the Grading of Recommendations Assessment, Development, and Evaluation Approach

    by Ibo MacDonald, Alexia Cavin-Trombert, Cécile Jaques, Gwenaëlle De Clifford-Faugère, Pieter A De Cock, Saskia N de Wildt, Dmytro Dmytriiev, Juliane Engel, Paola Claudia Fazio, Sylvia George, et al.

    [This corrects the article DOI: 10.2196/67930.].

  • Open Access

    French translation, cultural and digital adaptation of the state behavioral scale for sedation assessment in paediatric intensive care

    by Silvia Alvarado, Anne-Sylvie Ramelet, Gwenäelle De Clifford-Faugère, Guillaume Maitre, Juan-Miguel Manzano, Maria Helena Perez, Ibo MacDonald

  • Open Access

    Preoperative Administration of Levosimendan to Prevent Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery: A Retrospective Study

    by Laurence Boillat, Laure Pache-Wannaz, Guillaume Maitre, Frida Rizzati, Maria Pérez Marin, Vivianne Chanez, Stefano Di Bernardo, Maria-Helena Perez

    Background: Low cardiac output syndrome (LCOS) is a significant cause of postoperative morbidity and mortality in children with congenital heart disease. Prophylactic levosimendan is increasingly used to prevent LCOS, but its superiority to other strategies remains unproven. Based on the pharmacokinetics of levosimendan, we hypothesize that preoperative administration is beneficial for preventing LCOS in a specifically at-risk population. Methods: This is a retrospective single-center cohort study in a tertiary pediatric intensive care unit. All patients under one year of age undergoing surgery for congenital heart disease using cardiopulmonary bypass and receiving levosimendan within 24 h before or after surgery were included and classified into two groups: preoperative and postoperative administration. Results: Overall, 107 patients were included. Fifty-three patients (49.5%) received levosimendan before surgery, with significantly lower mortality, fewer LCOS markers, and lower LCOS scores compared to patients receiving levosimendan after surgery. Although not significant, the use of extracorporeal membrane oxygenation, renal replacement therapy, and temperature control was also lower in the preoperative group. There was no difference in mechanical ventilation duration and length of stay. Conclusions: Preoperative administration of levosimendan seems associated with a lower incidence of LCOS and reduced mortality in high-risk children with congenital heart surgery.

  • Open Access

    Corrigenda: Pain, Agitation, Delirium, and Iatrogenic Withdrawal Syndrome Management in Children Who Are Critically Ill: Protocol for a European Clinical Practice Guideline Using the Grading of Recommendations Assessment, Development, and Evaluation Approach (Preprint)

    by Ibo MacDonald, Alexia Cavin-Trombert, Cécile Jaques, Gwenaëlle De Clifford-Faugère, Pieter A De Cock, Saskia N de Wildt, Dmytro Dmytriiev, Juliane Engel, Paola Claudia Fazio, Sylvia George, et al.

  • Open Access

    The OCTO ‐Plus Intervention to Support Families of Chronically Critically Ill Children in Paediatric Critical Care: A Pilot Study

    by Mark T. Marston, Maria‐Helena Perez, Anne‐Sylvie Ramelet

    Background: Families of chronically critically ill (CCI) children admitted to paediatric critical care (PCC) experience significant and long‐lasting psychological distress. Structured family‐centred care consultations, using a family system approach, have shown promise in mitigating these effects. Though most studies in PCC are single‐component or lack methodological rigour. There is a need for complex, multi‐component interventions that address the evolving needs of families in PCC. Aim: To assess the feasibility of a co‐developed complex multi‐component family‐centred intervention to support families of CCI children on the PCC ward before effectiveness testing in a future clinical trial. Study Design: This single‐centre pilot feasibility study used a descriptive observational design guided by Bowen's feasibility framework. The intervention consisted of structured family consultations delivered by trained healthcare professionals, supported by interprofessional handovers. Quantitative data were collected at multiple time points using validated instruments to assess feasibility and limited efficacy outcomes. Results: Of 802 patients screened, 55 were eligible and 19 families enrolled (34.5%) representing 19 children and 27 parents. All allocated parents completed the intervention. Parents reported clinically meaningful reductions in acute stress, anxiety and depression from admission to follow‐up. Family functioning improved across most domains, and no parent met the threshold for PTSD at follow‐up. Satisfaction scores remained high throughout. Conclusions: This study demonstrates the clinical feasibility of a multi‐component family‐centred intervention for parents of children hospitalised in paediatric critical care. Findings suggest a protective effect on parental mental health and improved family functioning, supporting progression to a full‐scale effectiveness trial. Relevance to Clinical Practice: The OCTO‐Plus intervention offers a structured, family‐centred approach to support parents of CCI children in PCC. Its integration into clinical practice may enhance emotional regulation, communication and resilience, ultimately improving long‐term outcomes for families.


  • Open Access

    Population Pharmacokinetics of Levosimendan and its Metabolites OR-1855 and OR-1896 in Critically Ill Adults, Neonates and Infants on Veno-Arterial ECMO

    by Stéphane Bertin, Monia Guidi, David Haefliger, Paul Thoueille, Carine Bardinet, Laurent A. Decosterd, Maria-Helena Perez, Raphaël Giraud, Benjamin Assouline, Antoine Schneider, et al.

    Background and Objective Levosimendan is an inotrope and vasodilator agent commonly used in critical care, particularly to facilitate weaning from veno-arterial extracorporeal membrane oxygenation (VA-ECMO). However, critical illness and ECMO may affect levosimendan and its clinically relevant metabolites’ pharmacokinetics, potentially compromising circulating exposure and efficacy. There are limited data on levosimendan pharmacokinetics in critically ill patients, including those on VA-ECMO, thus emphasising the need for further research in this area. The aim of this study was to characterise the pharmacokinetic profile of levosimendan and its metabolites OR-1855 and OR-1896 in both critically ill adults and neonates/infants on VA-ECMO. Methods We conducted a bicentric, prospective, observational, pharmacokinetic study in critically ill adults and neonates/infants on VA-ECMO receiving levosimendan. Dosage history, sampling and clinical information were gathered. Samples were analysed by ultra-high-performance liquid chromatography coupled to tandem mass spectrometry using a validated highly sensitive method. A population pharmacokinetic model describing levosimendan and its metabolites OR-1855 (inactive) and OR-1896 (active, long-lasting) was developed using non-linear mixed-effects modelling (NONMEM). Model-based simulations were performed to compare exposures produced by various dosing scenarios. Results Twenty-one patients, 15 adults, three neonates and three infants, provided 155 blood samples. In adults, levosimendan was started at a rate of 0.05 µg/kg/min for 1–4 h, then increased to maintenance doses reaching 0.1 (n = 9), 0.15 (n = 3) or 0.2 (n = 3) µg/kg/min for a total infusion time of approximately 24 h. The neonates/infants received a continuous infusion of 0.1 µg/kg/min for 48 h. A two-compartment model best characterised levosimendan pharmacokinetics, with a transit compartment adequately describing the metabolites’ delayed synthesis. The transformation of OR-1855 into OR-1896 was 3.7-fold slower in neonates/infants than in adults. Model-based simulations using a standard 0.1-µg/kg/min regimen for 24 and 48 h in adults and neonates/infants, respectively, achieved lower levosimendan and metabolite concentrations in neonates/infants. Simulations using a 48-h infusion of 0.2 µg/kg/min in neonates/infants predict levosimendan concentrations comparable to those in adults receiving a 0.1-µg/kg/min maintenance dose. However, in this scenario, OR-1896 concentrations would remain considerably lower than in adults. Conclusions Our data indicate that levosimendan and its metabolites exhibit altered the pharmacokinetics in neonates/infants on VA-ECMO. Although some of these changes may be associated with ECMO, definitive conclusions on causality cannot be drawn, as age-dependent specific physiology and critically ill conditions may also contribute. These findings support the consideration of dose optimisation in this population. In adults, levosimendan pharmacokinetics seem unaffected, although metabolite concentrations appear slightly reduced compared with non-critically ill patients with heart failure. Graphical Abstract


  • Open Access

    Effects of Extracorporeal Membrane Oxygenation Circuits on Drug Sequestration: A Review of Ex Vivo Experiments

    by Stéphane Bertin, David Haefliger, Antoine G. Schneider, Raphaël Giraud, Maria-Helena Perez, Xavier Bechtold, Ermindo R. Di Paolo, Laura E. Rothuizen, Thierry Buclin, Françoise Livio

    Background: Extracorporeal membrane oxygenation (ECMO) can affect the disposition of drugs, notably by sequestering them in a circuit. This review aimed to provide a comprehensive summary of existing ex vivo studies investigating the impact of contemporary ECMO circuits on drug sequestration, and to examine the associations between the physicochemical properties of drugs, the features and settings of ECMO devices, and the extent of drug sequestration. Method: A comprehensive search was conducted to identify ex vivo studies that determined drug concentrations in ECMO circuits. Studies that did not allow for the proper assessment of drug loss by degradation were excluded. Drug characteristics and experimental conditions were recorded. Drug sequestration in the circuit was calculated as the difference between the drug loss measured in the ECMO circuit and the drug loss due to spontaneous degradation measured under control conditions. To identify predictors of drug sequestration, a stepwise multiple linear meta-regression was applied by testing the physicochemical properties of drugs and ECMO device features/settings. Results: A total of 40 studies were identified, of which 21 were included in the analysis, covering 41 drugs. The Maquet membrane oxygenator was the most used brand (73%). About half of the circuits were adult and half were pediatric. Our final regression model retained lipophilicity, and to a lesser extent ionization at a physiological pH, as significant predictors of drug sequestration (R2 0.44, relative standard error 23%). Protein binding had no additional effect. Anti-infectives were the most studied class of drugs (n = 28). Antibiotics were overall not significantly sequestered, while lipophilic drugs such as posaconazole, voriconazole, paracetamol, fentanyl, sufentanil, propofol, thiopental, dexmedetomidine and amiodarone were highly sequestered (≥50%). However, this sequestration occurred mainly within the first few hours of the experiments, possibly reflecting a saturation effect. Conclusions: Lipophilic drugs are significantly sequestered in ex vivo ECMO circuits, although this effect may be limited by early saturation.


  • Open Access

    Impact of a Nutrition Protocol on Vitamin D Supplementation in a Pediatric Intensive Care Unit: A Retrospective Cohort Study

    by Maria Pérez Marin, Vivianne Chanez, Guillaume Maitre, Laurence Boillat, Frida Rizzati, Pauline Lauwers, Maria-Helena Perez

    Background: Vitamin D deficiency (VDD) is highly prevalent in pediatric critically ill patients and is a potentially modifiable risk factor during critical illness. There are no established national or international recommendations for vitamin D supplementation in Pediatric Intensive Care Unit (PICU) patients. Objectives: This monocentric study aims to compare the practices regarding vitamin D supplementation before and after the introduction of a nutrition protocol (NP). Methods: We retrospectively analyzed vitamin D administration (time from PICU admission to initiation, amount of supplementation, accordance with existing guidelines) in children aged 0 to 16 who were admitted to the PICU of Lausanne University Hospital for more than 48 h the year before and the year after the introduction of a NP. Results: Vitamin D supplementation increased after NP introduction (95 IU per day more, p < 0.0001). More patients received vitamin D during their stay (95% after vs. 77% before, p < 0.0001). The dose adhered to NP recommendations for children under 12 and was higher for older children. According to Swiss guidelines for the general pediatric population, vitamin D supplementation was accurate in children under one year old before and after NP implementation. However, it was less than recommended for patients over one year old. Conclusions: The implementation of a NP significantly enhanced the scope of vitamin D supplementation. This study also highlights the practical limitations in meeting the recommended requirements with certain galenic formulations.